Redwood Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redwood Wealth Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,447	Closed	-$201K	–	283
2024 Q2	$201K	Buy	+2,447	New	+$204K	0.15%	118
2024 Q1	–	Sell	-2,797	Closed	-$270K	–	117
2023 Q4	$270K	Sell	2,797 -200	-7%	-$17.7K	0.3%	96
2023 Q3	$265K	Sell	2,997 -100	-3%	-$8.9K	0.31%	96
2023 Q2	$268K	Sell	3,097 -75	-2%	-$7.06K	0.3%	97
2023 Q1	$308K	Hold	3,172	–	–	0.35%	84
2022 Q4	$328K	Buy	+3,172	New	+$298K	0.41%	74

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Redwood Wealth Management Group's BMRN Position: Q3 2024 in Review

Redwood Wealth Management Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,447 shares — an estimated $201K sold.

Redwood Wealth Management Group first reported a position in BMRN in Q4 2022 and held it in 6 quarters. The position peaked at $328K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Redwood Wealth Management Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Redwood Wealth Management Group sold 2,447 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $201K.
Redwood Wealth Management Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 6 quarters.
Redwood Wealth Management Group's BioMarin Pharmaceuticals position peaked at $328K in Q4 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Redwood Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.